Identify and Engage Medical Experts with Ease
PHILADELPHIA, March 24, 2015 /PRNewswire/ -- ACI Clinicalannounces a new solution for Life Sciences companies facing the growing difficulty surrounding the identification and engagement of independent medical experts. With over a decade of experience building and managing a global network of medical thought leaders, ACI offers a complete solution that simplifies all aspects of the recruitment, contracting and payment process. With pressure from new regulations like the Sunshine Payments Act, clients can contact ACI today to find the expertise needed for everything from study design to clinical consulting to full service Endpoint Adjudication and Data Monitoring Committee solutions.
Common challenges in Engaging Medical Experts
Medical experts are frequently contracted by pharmaceutical, biotech and device companies to provide thought leadership expertise at various points of development and post-marketing. Experts often serve as consultants for study design and safety issues, or as members of independent data review committees.
Finding the right match for unique project needs while complying with regulations around Health Care Provider (HCP) transfers of value can bring many challenges that ACI Clinical can help to solve:
- Opportunity cost of spending time and resources on trying to find the right consultants
- Determining individual experience, availability, fit and conflicts of interest
- Managing the sensitive expert-customer relationship
- Proving Fair Market Value (FMV) compliance for pay rates
- Meeting local, national, international, academic and institutional HCP payment requirements
Assistance with Fair Market Value (FMV) Determinations
Although various mechanisms are in place to establish HCP value, such as MGMA reports, these rates often don't reflect the added-value of leading medical experts. Thought-leader expertise is so rare that there is no readily available published source of fair market rates for these individuals. Given ACI's long history of managing independent expert committees – from identification and vetting to negotiating rates and managing payments – ACI holds unique insight into the actual data. Clients looking for medical expert FMV payment information can turn to ACI for real-world contractual data on hourly rates of experts in over 20 countries.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
